6CM
AVTX icon

683 Capital Management’s Avalo Therapeutics AVTX Stock Holding History

683 Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$849K Hold
56,850
– – 0.04% 145
2025
Q4 		$1.03M Buy
+56,850
New +$960K 0.04% 138

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

683 Capital Management's AVTX Position: Q1 2026 in Review

683 Capital Management held its Avalo Therapeutics (AVTX) position steady in Q1 2026 at 56,850 shares worth $849K. The position accounts for 0.04% of the portfolio, ranked #145.

683 Capital Management first reported a position in AVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.03M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • 683 Capital Management held 56,850 shares of Avalo Therapeutics worth $849K as of Q1 2026.
  • 683 Capital Management left its Avalo Therapeutics share count unchanged in Q1 2026.
  • Avalo Therapeutics made up 0.04% of 683 Capital Management's portfolio in Q1 2026, its #145 holding.
  • 683 Capital Management first reported a position in Avalo Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 683 Capital Management's Avalo Therapeutics position peaked at $1.03M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.